Sodium Glucose Co-Transporter 2 Inhibitors and the Cardiovascular System: Current Knowledge and Future Expectations
Heart Int. 2023 Dec 1;17(2):12-18. doi: 10.17925/HI.2023.17.2.12. eCollection 2023.ABSTRACTDiabetic cardiomyopathy is a well-recognized clinical entity and reflects a complex relationship between metabolic substrates and myocardial function. Sodium glucose co-transporter 2 (SGLT2) inhibitors are antidiabetic agents that are found to exert multiple cardioprotective effects. Large clinical trials showed their beneficial effects on patients with heart failure, reducing the rates of rehospitalizations and improving kidney function. The aim of this review is to summarize the latest evidence in the literature regarding the multi...
Source: Heart International - February 29, 2024 Category: Cardiology Authors: Ioannis Boutsikos Eleftherios Beltsios Bastian Schmack Ioannis Pantazopoulos Dimitrios G Chatzis Source Type: research
Conduction System Pacing: Have We Finally Found the Holy Grail of Physiological Pacing?
Heart Int. 2023 Dec 1;17(2):2-5. doi: 10.17925/HI.2023.17.2.2. eCollection 2023.ABSTRACTThe late fifties are considered a high point in the history of cardiac pacing, since this era is marked by the first pacemaker implantation, which has since evolved into life-saving therapy. Right ventricular apical and biventricular pacing are the classic techniques that are recommended as first-l ine approaches for most indications in current guidelines. However, conduction system pacing has emerged as being able to deliver a more physiological form of pacing and is becoming mainstream practice in a growing number of centres. In this ...
Source: Heart International - February 29, 2024 Category: Cardiology Authors: Myriam Kaddour Haran Burri Source Type: research
Assessment and Management of Ischaemic Heart Disease in Non-Cardiac Surgery
Heart Int. 2023 Dec 1;17(2):19-26. doi: 10.17925/HI.2023.17.2.19. eCollection 2023.ABSTRACTIn the setting of non-cardiac surgery, cardiac complications contribute to over a third of perioperative deaths. With over 230 million major surgeries performed annually, and an increasing prevalence of cardiovascular risk factors and ischaemic heart disease, the incidence of perioperative myocardial infarction is also rising. The recent European Society of Cardiology guidelines on cardiovascular risk in noncardiac surgery elevated practices aiming to identify those at most risk, including biomarker monitoring and stress testing. How...
Source: Heart International - February 29, 2024 Category: Cardiology Authors: Holly Morgan Saad M Ezad Haseeb Rahman Kalpa De Silva Judith S L Partridge Divaka Perera Source Type: research
Sarcopenic Obesity as a Risk Factor for Cardiovascular Disease: An Underrecognized Clinical Entity
This article covers the available literature regarding the definition, diagnostic criteria, and prevalence of SO, with available evidence linking it to CVD, metabolic disease and mortality, and an overview of current directives on management.PMID:38419720 | PMC:PMC10897945 | DOI:10.17925/HI.2023.17.2.6 (Source: Heart International)
Source: Heart International - February 29, 2024 Category: Cardiology Authors: Aditya John Binu Nitin Kapoor Saptarshi Bhattacharya Kamal Kishor Sanjay Kalra Source Type: research
Bempedoic Acid: Lipid Lowering for Cardiovascular Disease Prevention
Heart Int. 2023 Nov 1;17(2):27-34. doi: 10.17925/HI.2023.17.2.1. eCollection 2023.ABSTRACTThe management of low-density lipoprotein cholesterol (LDL-C) levels is a central strategy for the prevention of atherosclerotic cardiovascular disease. Current United States (2018 American Heart Association/American College of Cardiology/Multisociety) and European (2019 European Society of Cardiology/European Atherosclerosis Society) guidelines endorse statin therapy as the first-line therapy for pharmacologic LDL-C lowering. However, in clinical practice up to 30% of patients report partial or complete intolerance to statin therapy....
Source: Heart International - February 29, 2024 Category: Cardiology Authors: Michael Albosta Jelani K Grant Erin D Michos Source Type: research
Sodium Glucose Co-Transporter 2 Inhibitors and the Cardiovascular System: Current Knowledge and Future Expectations
Heart Int. 2023 Dec 1;17(2):12-18. doi: 10.17925/HI.2023.17.2.12. eCollection 2023.ABSTRACTDiabetic cardiomyopathy is a well-recognized clinical entity and reflects a complex relationship between metabolic substrates and myocardial function. Sodium glucose co-transporter 2 (SGLT2) inhibitors are antidiabetic agents that are found to exert multiple cardioprotective effects. Large clinical trials showed their beneficial effects on patients with heart failure, reducing the rates of rehospitalizations and improving kidney function. The aim of this review is to summarize the latest evidence in the literature regarding the multi...
Source: Heart International - February 29, 2024 Category: Cardiology Authors: Ioannis Boutsikos Eleftherios Beltsios Bastian Schmack Ioannis Pantazopoulos Dimitrios G Chatzis Source Type: research
Conduction System Pacing: Have We Finally Found the Holy Grail of Physiological Pacing?
Heart Int. 2023 Dec 1;17(2):2-5. doi: 10.17925/HI.2023.17.2.2. eCollection 2023.ABSTRACTThe late fifties are considered a high point in the history of cardiac pacing, since this era is marked by the first pacemaker implantation, which has since evolved into life-saving therapy. Right ventricular apical and biventricular pacing are the classic techniques that are recommended as first-l ine approaches for most indications in current guidelines. However, conduction system pacing has emerged as being able to deliver a more physiological form of pacing and is becoming mainstream practice in a growing number of centres. In this ...
Source: Heart International - February 29, 2024 Category: Cardiology Authors: Myriam Kaddour Haran Burri Source Type: research
Assessment and Management of Ischaemic Heart Disease in Non-Cardiac Surgery
Heart Int. 2023 Dec 1;17(2):19-26. doi: 10.17925/HI.2023.17.2.19. eCollection 2023.ABSTRACTIn the setting of non-cardiac surgery, cardiac complications contribute to over a third of perioperative deaths. With over 230 million major surgeries performed annually, and an increasing prevalence of cardiovascular risk factors and ischaemic heart disease, the incidence of perioperative myocardial infarction is also rising. The recent European Society of Cardiology guidelines on cardiovascular risk in noncardiac surgery elevated practices aiming to identify those at most risk, including biomarker monitoring and stress testing. How...
Source: Heart International - February 29, 2024 Category: Cardiology Authors: Holly Morgan Saad M Ezad Haseeb Rahman Kalpa De Silva Judith S L Partridge Divaka Perera Source Type: research
Sarcopenic Obesity as a Risk Factor for Cardiovascular Disease: An Underrecognized Clinical Entity
This article covers the available literature regarding the definition, diagnostic criteria, and prevalence of SO, with available evidence linking it to CVD, metabolic disease and mortality, and an overview of current directives on management.PMID:38419720 | PMC:PMC10897945 | DOI:10.17925/HI.2023.17.2.6 (Source: Heart International)
Source: Heart International - February 29, 2024 Category: Cardiology Authors: Aditya John Binu Nitin Kapoor Saptarshi Bhattacharya Kamal Kishor Sanjay Kalra Source Type: research
Bempedoic Acid: Lipid Lowering for Cardiovascular Disease Prevention
Heart Int. 2023 Nov 1;17(2):27-34. doi: 10.17925/HI.2023.17.2.1. eCollection 2023.ABSTRACTThe management of low-density lipoprotein cholesterol (LDL-C) levels is a central strategy for the prevention of atherosclerotic cardiovascular disease. Current United States (2018 American Heart Association/American College of Cardiology/Multisociety) and European (2019 European Society of Cardiology/European Atherosclerosis Society) guidelines endorse statin therapy as the first-line therapy for pharmacologic LDL-C lowering. However, in clinical practice up to 30% of patients report partial or complete intolerance to statin therapy....
Source: Heart International - February 29, 2024 Category: Cardiology Authors: Michael Albosta Jelani K Grant Erin D Michos Source Type: research
Sodium Glucose Co-Transporter 2 Inhibitors and the Cardiovascular System: Current Knowledge and Future Expectations
Heart Int. 2023 Dec 1;17(2):12-18. doi: 10.17925/HI.2023.17.2.12. eCollection 2023.ABSTRACTDiabetic cardiomyopathy is a well-recognized clinical entity and reflects a complex relationship between metabolic substrates and myocardial function. Sodium glucose co-transporter 2 (SGLT2) inhibitors are antidiabetic agents that are found to exert multiple cardioprotective effects. Large clinical trials showed their beneficial effects on patients with heart failure, reducing the rates of rehospitalizations and improving kidney function. The aim of this review is to summarize the latest evidence in the literature regarding the multi...
Source: Heart International - February 29, 2024 Category: Cardiology Authors: Ioannis Boutsikos Eleftherios Beltsios Bastian Schmack Ioannis Pantazopoulos Dimitrios G Chatzis Source Type: research
